Circulating lncRNA IFNG‐AS1 expression correlates with increased disease risk, higher disease severity and elevated inflammation in patients with coronary artery disease

Abstract

Circulating lncRNA IFNG-AS1 expression correlates with increased disease risk, higher disease severity and elevated inflammation in CAD patients.

The correlation of long non‐coding RNA intersectin 1‐2 with disease risk, disease severity, inflammation, and prognosis of acute ischemic stroke

“…Similarly, few studies have been performed to investigate the role of lnc‐ITSN1‐2 in inflammation‐related diseases. Just three previous studies reveal that the enhanced lnc‐ITSN1‐2 expression is associated with elevated inflammation and disease severity of RA, CAD, and sepsis . For instance, a previous study reveals that lnc‐ITSN1‐2 is positively correlated with disease activity score in 28 joints, as well as CRP in RA patients .…”

“…Long non‐coding RNA intersectin 1‐2 (lnc‐ITSN1‐2) is a lncRNA located on chromatin 21 with a length of 451 bp and with NONCODE gene ID NONHSAG032726.2 . The function of lnc‐ITSN1‐2 is reported by only a few studies, which reveal that it acts as a potential biomarker in inflammation‐related diseases (such as rheumatoid arthritis (RA), sepsis, and coronary artery disease (CAD)) . Considering the abovementioned data and the implication of inflammation in AIS, we hypothesized that lnc‐ITSN1‐2 can also promote the pathological progression in AIS patients, while relevant research on the role of lnc‐ITSN1‐2 in AIS has not been studied before .…”

“…11 The function of lnc-ITSN1-2 is reported by only a few studies, which reveal that it acts as a potential biomarker in inflammation-related diseases (such as rheumatoid arthritis (RA), sepsis, and coronary artery disease (CAD)). [11][12][13] Considering the abovementioned data and the implication of inflammation in AIS, we hypothesized that lnc-ITSN1-2 can also promote the pathological progression in AIS patients, while relevant research on the role of lnc-ITSN1-2 in AIS has not been studied before. 14 Thus, we performed this study to explore the predictive value of lnc-ITSN1-2 for AIS risk and investigate its correlation with disease severity, inflammation, and recurrence-free survival (RFS) in AIS patients.…”

Elevated circulating lnc‐ANRIL/miR‐125a axis level predicts higher risk, more severe disease condition, and worse prognosis of sepsis

“…These mechanistic experiments indicate that miR‐125a is a crucial regulator in inflammation and immune responses, which might explain the results in our study that miR‐125a plasma expression could predict sepsis risk, and was negatively correlated with severity and pro‐inflammatory cytokines levels in sepsis patients. In addition, there is a report showing that U6 might not be an appropriate internal reference for miRNAs detection; however, for circulating miR‐125a expression detection, there are still mounting studies using U6 as an internal reference …”

“…Recently, the wide application of high‐throughput sequencing benefiting from the progress in technology and decrease in cost has led to incremental improvements in the exploration of sepsis pathogenesis, among which noncoding RNA takes a critical place in the participation of inflammation, immune disorder, and organ dysfunction in sepsis . With respect to the values of noncoding RNAs to be biomarkers or therapeutic targets in sepsis patients, long noncoding RNA (lncRNA) and microRNA (miRNA) are the most implicated ones . Lnc‐antisense noncoding RNA in the INK4 locus (ANRIL) is a lncRNA located on chromosome 9p21 region and transcribed by RNA polymerase II and is indicated in the regulation of inflammation and immune responses .…”